Compare Fortive Corporation Common Stock (FTV) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortive Corporation Common Stock vs Organon & Co. Common Stock — how do they compare? Fortive Corporation Common Stock trades at $57.21 (market cap $17.54B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Fortive Corporation Common Stock is far larger — about 4.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Fortive Corporation Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| FTV | OGN | |
|---|---|---|
Market Cap | $17.54B | $3.62B |
Volume | 1,898,662 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $64.09 | $13.81 |
52-Week Low | $48.49 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.67B | $11.04B |
Dividend Yield | 0.48% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortive Corporation (FTV) trades at $58.07, up 1.22% today, with a neutral technical signal and a consensus analyst price target of $63.33. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue growth is modest, but profitability remains solid with a 12.38% net income margin. Recent news highlights product launches and a dividend increase, while institutional activity includes mixed buying and selling.
The outlook is cautiously positive, supported by raised 2026 guidance and core growth acceleration. Key risks include competitive pressures and macroeconomic headwinds. Analyst sentiment is mixed, with 36.67% buy ratings, but the stock offers potential upside to the consensus target if execution continues to improve.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortive Corporation Common Stock
Fortive provides industrial and healthcare technology solutions. Its products and software support measurement, maintenance, worker safety, instrument sterilization, and clinical workflows.
Read more on FTV →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
